New HPV vaccine confirmed safe: AusVaxSafety
Data from AusVaxSafety has confirmed the safety of new human papillomavirus (HPV) vaccine, Gardasil9®, in Australian adolescents. The vaccine was added to the National Immunisation Program earlier this year for adolescent males and females, and is mainly delivered through free, school-based immunisation programs, with some doses also given by GPs.
The new vaccine protects against 9 different types of HPV (5 more types than the previous vaccine) and prevents HPV-related cancers, such as cervical, and head and neck cancer.
Over 8,000 parents of 11-14 year olds who were vaccinated this year have provided feedback to an SMS-based survey of safety after the jab, which is sent out to parents 3 days after vaccination using the automated Smartvax software.
No safety concerns for the new vaccine have been identified since AusVaxSafety began monitoring and reporting in February 2018. The most common and expected event described by parents was injection site reactions, which was found in 3.8% of reports.
This world-first active vaccine safety data for the new HPV vaccine was showcased at the 32nd International Papillomavirus Conference in Sydney last week.
“We are very excited to add to the global body of research regarding the safety of Gardasil9®, and hope this information will support the wider uptake of this life-saving vaccine,” said Professor Kristine Macartney, Director of the National Centre for Immunisation Research and Surveillance (NCIRS), who lead the AusVaxSafety surveillance system.
More HPV vaccine safety surveillance results, as well as results for other vaccines such as those protecting against whooping cough, shingles and influenza, are available on the AusVaxSafety website. Earlier this year, AusVaxSafety collected data confirming the safety of influenza vaccines in more than 167,000 children and adults surveyed.